Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 41 entries
Sorted by: Best Match Show Resources per page
Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy.

Haematologica

Gustine JN, Sarosiek S, Flynn CA, Meid K, Leventoff C, White T, Guerrera ML, Xu L, Kofides A, Tsakmaklis N, Munshi M, Demos M, Patterson CJ, Liu X, Yang G, Hunter ZR, Branagan AR, Treon SP, Castillo JJ.
PMID: 34162182
Haematologica. 2021 Jun 24; doi: 10.3324/haematol.2021.279112. Epub 2021 Jun 24.

Ibrutinib is highly active and produces long-term responses in patients with Waldenström macroglobulinemia (WM), but acquired resistance can occur with prolonged treatment. We therefore evaluated the natural history and treatment outcomes in 51 WM patients with acquired resistance to...

Cite
Gustine JN, Sarosiek S, Flynn CA, et al. Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy. Haematologica. 2021;doi: 10.3324/haematol.2021.279112.
Gustine, J. N., Sarosiek, S., Flynn, C. A., Meid, K., Leventoff, C., White, T., Guerrera, M. L., Xu, L., Kofides, A., Tsakmaklis, N., Munshi, M., Demos, M., Patterson, C. J., Liu, X., Yang, G., Hunter, Z. R., Branagan, A. R., Treon, S. P., & Castillo, J. J. (2021). Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy. Haematologica, . https://doi.org/10.3324/haematol.2021.279112
Gustine, Joshua N, et al. "Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy." Haematologica vol. (2021). doi: https://doi.org/10.3324/haematol.2021.279112
Gustine JN, Sarosiek S, Flynn CA, Meid K, Leventoff C, White T, Guerrera ML, Xu L, Kofides A, Tsakmaklis N, Munshi M, Demos M, Patterson CJ, Liu X, Yang G, Hunter ZR, Branagan AR, Treon SP, Castillo JJ. Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy. Haematologica. 2021 Jun 24; doi: 10.3324/haematol.2021.279112. Epub 2021 Jun 24. PMID: 34162182.
Copy Download .nbib Format: NLM
Medical Management of Hemodynamically Unstable Sinoatrial Node Dysfunction in a Patient With Intracardiac Lymphoma.

JACC. CardioOncology

Martz CA, Jarbeau JF, Castillo JJ, Fisher DC, Nohria A.
PMID: 34396343
JACC CardioOncol. 2021 Jun 15;3(2):326-329. doi: 10.1016/j.jaccao.2021.03.003. eCollection 2021 Jun.

No abstract available.

Cite
Martz CA, Jarbeau JF, Castillo JJ, et al. Medical Management of Hemodynamically Unstable Sinoatrial Node Dysfunction in a Patient With Intracardiac Lymphoma. JACC CardioOncol. 2021;3(2):326-329doi: 10.1016/j.jaccao.2021.03.003.
Martz, C. A., Jarbeau, J. F., Castillo, J. J., Fisher, D. C., & Nohria, A. (2021). Medical Management of Hemodynamically Unstable Sinoatrial Node Dysfunction in a Patient With Intracardiac Lymphoma. JACC. CardioOncology, 3(2), 326-329. https://doi.org/10.1016/j.jaccao.2021.03.003
Martz, Colin A, et al. "Medical Management of Hemodynamically Unstable Sinoatrial Node Dysfunction in a Patient With Intracardiac Lymphoma." JACC. CardioOncology vol. 3,2 (2021): 326-329. doi: https://doi.org/10.1016/j.jaccao.2021.03.003
Martz CA, Jarbeau JF, Castillo JJ, Fisher DC, Nohria A. Medical Management of Hemodynamically Unstable Sinoatrial Node Dysfunction in a Patient With Intracardiac Lymphoma. JACC CardioOncol. 2021 Jun 15;3(2):326-329. doi: 10.1016/j.jaccao.2021.03.003. eCollection 2021 Jun. PMID: 34396343; PMCID: PMC8352225.
Copy Download .nbib Format: NLM
How to Sequence Therapies in Waldenström Macroglobulinemia.

Current treatment options in oncology

Sarosiek S, Treon SP, Castillo JJ.
PMID: 34426943
Curr Treat Options Oncol. 2021 Aug 23;22(10):92. doi: 10.1007/s11864-021-00890-9.

OPINION STATEMENT: There are multiple treatment options in patients with Waldenström macroglobulinemia, including chemotherapy, monoclonal antibodies, proteasome inhibitors, and covalent Bruton tyrosine kinase (BTK) inhibitors. The choice of therapy should take into account the patient's clinical presentation, comorbidities, and...

Cite
Sarosiek S, Treon SP, Castillo JJ. How to Sequence Therapies in Waldenström Macroglobulinemia. Curr Treat Options Oncol. 2021;22(10):92doi: 10.1007/s11864-021-00890-9.
Sarosiek, S., Treon, S. P., & Castillo, J. J. (2021). How to Sequence Therapies in Waldenström Macroglobulinemia. Current treatment options in oncology, 22(10), 92. https://doi.org/10.1007/s11864-021-00890-9
Sarosiek, Shayna, et al. "How to Sequence Therapies in Waldenström Macroglobulinemia." Current treatment options in oncology vol. 22,10 (2021): 92. doi: https://doi.org/10.1007/s11864-021-00890-9
Sarosiek S, Treon SP, Castillo JJ. How to Sequence Therapies in Waldenström Macroglobulinemia. Curr Treat Options Oncol. 2021 Aug 23;22(10):92. doi: 10.1007/s11864-021-00890-9. PMID: 34426943.
Copy Download .nbib Format: NLM
Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib.

British journal of haematology

Castillo JJ, LaMacchia J, Flynn CA, Sarosiek S, Pozdnyakova O, Treon SP.
PMID: 34355802
Br J Haematol. 2021 Nov;195(3):466-468. doi: 10.1111/bjh.17759. Epub 2021 Aug 06.

No abstract available.

Cite
Castillo JJ, LaMacchia J, Flynn CA, et al. Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib. Br J Haematol. 2021;195(3):466-468doi: 10.1111/bjh.17759.
Castillo, J. J., LaMacchia, J., Flynn, C. A., Sarosiek, S., Pozdnyakova, O., & Treon, S. P. (2021). Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib. British journal of haematology, 195(3), 466-468. https://doi.org/10.1111/bjh.17759
Castillo, Jorge J, et al. "Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib." British journal of haematology vol. 195,3 (2021): 466-468. doi: https://doi.org/10.1111/bjh.17759
Castillo JJ, LaMacchia J, Flynn CA, Sarosiek S, Pozdnyakova O, Treon SP. Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib. Br J Haematol. 2021 Nov;195(3):466-468. doi: 10.1111/bjh.17759. Epub 2021 Aug 06. PMID: 34355802.
Copy Download .nbib Format: NLM
POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis.

Clinical lymphoma, myeloma & leukemia

Jurczyszyn A, Castillo JJ, Olszewska-Szopa M, Kumar L, Thibaud S, Richter J, Flicker K, Fiala M, Vij R, Yi S, Xu F, Silbermann R, Gaisan CM, Ocio EM, Waszczuk-Gajda A, Crusoe EQ, Salomon-Perzyński A, Hus I, Valls JD, Gozzetti A, Czepiel J, Krzanowska K, Chappell A, Chellapuram SK, Suska A, Vesole DH.
PMID: 34844892
Clin Lymphoma Myeloma Leuk. 2021 Oct 31; doi: 10.1016/j.clml.2021.10.007. Epub 2021 Oct 31.

POEMS syndrome, a rare plasma cell disorder, is challenging both in the diagnostic and therapeutic management. We present real word retrospective analysis of 108 cases analyzing clinical features and therapeutic modes. We compare our results with the available literature....

Cite
Jurczyszyn A, Castillo JJ, Olszewska-Szopa M, et al. POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis. Clin Lymphoma Myeloma Leuk. 2021;doi: 10.1016/j.clml.2021.10.007.
Jurczyszyn, A., Castillo, J. J., Olszewska-Szopa, M., Kumar, L., Thibaud, S., Richter, J., Flicker, K., Fiala, M., Vij, R., Yi, S., Xu, F., Silbermann, R., Gaisan, C. M., Ocio, E. M., Waszczuk-Gajda, A., Crusoe, E. Q., Salomon-Perzyński, A., Hus, I., Valls, J. D., Gozzetti, A., Czepiel, J., Krzanowska, K., Chappell, A., Chellapuram, S. K., Suska, A., & Vesole, D. H. (2021). POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis. Clinical lymphoma, myeloma & leukemia, . https://doi.org/10.1016/j.clml.2021.10.007
Jurczyszyn, Artur, et al. "POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis." Clinical lymphoma, myeloma & leukemia vol. (2021). doi: https://doi.org/10.1016/j.clml.2021.10.007
Jurczyszyn A, Castillo JJ, Olszewska-Szopa M, Kumar L, Thibaud S, Richter J, Flicker K, Fiala M, Vij R, Yi S, Xu F, Silbermann R, Gaisan CM, Ocio EM, Waszczuk-Gajda A, Crusoe EQ, Salomon-Perzyński A, Hus I, Valls JD, Gozzetti A, Czepiel J, Krzanowska K, Chappell A, Chellapuram SK, Suska A, Vesole DH. POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis. Clin Lymphoma Myeloma Leuk. 2021 Oct 31; doi: 10.1016/j.clml.2021.10.007. Epub 2021 Oct 31. PMID: 34844892.
Copy Download .nbib Format: NLM
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.

Blood

Yang G, Wang J, Tan L, Munshi M, Liu X, Kofides A, Chen JG, Tsakmaklis N, Demos MG, Guerrera ML, Xu L, Hunter ZR, Che J, Patterson CJ, Meid K, Castillo JJ, Munshi NC, Anderson KC, Cameron M, Buhrlage SJ, Gray NS, Treon SP.
PMID: 34132782
Blood. 2021 Nov 18;138(20):1966-1979. doi: 10.1182/blood.2021011405.

Activating mutations in MYD88 promote malignant cell growth and survival through hematopoietic cell kinase (HCK)-mediated activation of Bruton tyrosine kinase (BTK). Ibrutinib binds to BTKCys481 and is active in B-cell malignancies driven by mutated MYD88. Mutations in BTKCys481, particularly...

Cite
Yang G, Wang J, Tan L, et al. The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. Blood. 2021;138(20):1966-1979doi: 10.1182/blood.2021011405.
Yang, G., Wang, J., Tan, L., Munshi, M., Liu, X., Kofides, A., Chen, J. G., Tsakmaklis, N., Demos, M. G., Guerrera, M. L., Xu, L., Hunter, Z. R., Che, J., Patterson, C. J., Meid, K., Castillo, J. J., Munshi, N. C., Anderson, K. C., Cameron, M., Buhrlage, S. J., Gray, N. S., & Treon, S. P. (2021). The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. Blood, 138(20), 1966-1979. https://doi.org/10.1182/blood.2021011405
Yang, Guang, et al. "The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance." Blood vol. 138,20 (2021): 1966-1979. doi: https://doi.org/10.1182/blood.2021011405
Yang G, Wang J, Tan L, Munshi M, Liu X, Kofides A, Chen JG, Tsakmaklis N, Demos MG, Guerrera ML, Xu L, Hunter ZR, Che J, Patterson CJ, Meid K, Castillo JJ, Munshi NC, Anderson KC, Cameron M, Buhrlage SJ, Gray NS, Treon SP. The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. Blood. 2021 Nov 18;138(20):1966-1979. doi: 10.1182/blood.2021011405. PMID: 34132782; PMCID: PMC8602936.
Copy Download .nbib Format: NLM
Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic.

HemaSphere

Talaulikar D, Advani RH, Branagan AR, Buske C, Dimopoulos MA, D'Sa S, Kersten MJ, Leblond V, Minnema MC, Owen RG, Palomba ML, Tedeschi A, Trotman J, Varettoni M, Vos JM, Treon SP, Kastritis E, Castillo JJ.
PMID: 32803133
Hemasphere. 2020 Jul 30;4(4):e433. doi: 10.1097/HS9.0000000000000433. eCollection 2020 Aug.

In the light of the COVID-19 pandemic, the International Workshop on Waldenström Macroglobulinemia (IWWM) Treatment Recommendations Panel felt the need to provide a consensus statement for the management of Waldenström Macroglobulinemia (WM) patients during this challenging time. We followed...

Cite
Talaulikar D, Advani RH, Branagan AR, et al. Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. Hemasphere. 2020;4(4):e433doi: 10.1097/HS9.0000000000000433.
Talaulikar, D., Advani, R. H., Branagan, A. R., Buske, C., Dimopoulos, M. A., D'Sa, S., Kersten, M. J., Leblond, V., Minnema, M. C., Owen, R. G., Palomba, M. L., Tedeschi, A., Trotman, J., Varettoni, M., Vos, J. M., Treon, S. P., Kastritis, E., & Castillo, J. J. (2020). Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. HemaSphere, 4(4), e433. https://doi.org/10.1097/HS9.0000000000000433
Talaulikar, Dipti, et al. "Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic." HemaSphere vol. 4,4 (2020): e433. doi: https://doi.org/10.1097/HS9.0000000000000433
Talaulikar D, Advani RH, Branagan AR, Buske C, Dimopoulos MA, D'Sa S, Kersten MJ, Leblond V, Minnema MC, Owen RG, Palomba ML, Tedeschi A, Trotman J, Varettoni M, Vos JM, Treon SP, Kastritis E, Castillo JJ. Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. Hemasphere. 2020 Jul 30;4(4):e433. doi: 10.1097/HS9.0000000000000433. eCollection 2020 Aug. PMID: 32803133; PMCID: PMC7410025.
Copy Download .nbib Format: NLM
Do viscosity and wettability of fluoride varnishes affect their fluoride release?.

Journal of clinical and experimental dentistry

Asian J, Quenta E, Castillo JL.
PMID: 33680323
J Clin Exp Dent. 2021 Mar 01;13(3):e221-e226. doi: 10.4317/jced.56985. eCollection 2021 Mar.

BACKGROUND: There are several brands of fluoride varnishes in the market, but the dynamics of fluoride release from each one might be different. The purpose of this study was to evaluate in vitro the release of fluorides by fluoride...

Cite
Asian J, Quenta E, Castillo JL. Do viscosity and wettability of fluoride varnishes affect their fluoride release?. J Clin Exp Dent. 2021;13(3):e221-e226doi: 10.4317/jced.56985.
Asian, J., Quenta, E., & Castillo, J. L. (2021). Do viscosity and wettability of fluoride varnishes affect their fluoride release?. Journal of clinical and experimental dentistry, 13(3), e221-e226. https://doi.org/10.4317/jced.56985
Asian, Jackeline, et al. "Do viscosity and wettability of fluoride varnishes affect their fluoride release?." Journal of clinical and experimental dentistry vol. 13,3 (2021): e221-e226. doi: https://doi.org/10.4317/jced.56985
Asian J, Quenta E, Castillo JL. Do viscosity and wettability of fluoride varnishes affect their fluoride release?. J Clin Exp Dent. 2021 Mar 01;13(3):e221-e226. doi: 10.4317/jced.56985. eCollection 2021 Mar. PMID: 33680323; PMCID: PMC7920555.
Copy Download .nbib Format: NLM
What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapy.

Blood advances

Treon SP, Castillo JJ.
PMID: 29296899
Blood Adv. 2017 Nov 28;1(25):2486-2490. doi: 10.1182/bloodadvances.2017005637. eCollection 2017 Nov 28.

No abstract available.

Cite
Treon SP, Castillo JJ. What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapy. Blood Adv. 2017;1(25):2486-2490doi: 10.1182/bloodadvances.2017005637.
Treon, S. P., & Castillo, J. J. (2017). What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapy. Blood advances, 1(25), 2486-2490. https://doi.org/10.1182/bloodadvances.2017005637
Treon, Steven P, and Castillo, Jorge J. "What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapy." Blood advances vol. 1,25 (2017): 2486-2490. doi: https://doi.org/10.1182/bloodadvances.2017005637
Treon SP, Castillo JJ. What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapy. Blood Adv. 2017 Nov 28;1(25):2486-2490. doi: 10.1182/bloodadvances.2017005637. eCollection 2017 Nov 28. PMID: 29296899; PMCID: PMC5729614.
Copy Download .nbib Format: NLM
Bonding failure is similar if brackets are bonded either with resin-modified glass ionomer cements (RM-GICs) or composite resin cements (CRCs).

The journal of evidence-based dental practice

Castillo JL.
PMID: 23177495
J Evid Based Dent Pract. 2012 Dec;12(4):193-5. doi: 10.1016/j.jebdp.2012.09.010.

No abstract available.

Cite
Castillo JL. Bonding failure is similar if brackets are bonded either with resin-modified glass ionomer cements (RM-GICs) or composite resin cements (CRCs). J Evid Based Dent Pract. 2012;12(4):193-5doi: 10.1016/j.jebdp.2012.09.010.
Castillo, J. L. (2012). Bonding failure is similar if brackets are bonded either with resin-modified glass ionomer cements (RM-GICs) or composite resin cements (CRCs). The journal of evidence-based dental practice, 12(4), 193-5. https://doi.org/10.1016/j.jebdp.2012.09.010
Castillo, Jorge L. "Bonding failure is similar if brackets are bonded either with resin-modified glass ionomer cements (RM-GICs) or composite resin cements (CRCs)." The journal of evidence-based dental practice vol. 12,4 (2012): 193-5. doi: https://doi.org/10.1016/j.jebdp.2012.09.010
Castillo JL. Bonding failure is similar if brackets are bonded either with resin-modified glass ionomer cements (RM-GICs) or composite resin cements (CRCs). J Evid Based Dent Pract. 2012 Dec;12(4):193-5. doi: 10.1016/j.jebdp.2012.09.010. PMID: 23177495.
Copy Download .nbib Format: NLM
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia.

Leukemia

Castillo JJ, Meid K, Gustine JN, Leventoff C, White T, Flynn CA, Sarosiek S, Demos MG, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, Xu L, Yang G, Branagan AR, O'Donnell E, Raje N, Yee AJ, Patterson CJ, Hunter ZR, Treon SP.
PMID: 34531537
Leukemia. 2021 Sep 16; doi: 10.1038/s41375-021-01417-9. Epub 2021 Sep 16.

Herein, we present the final report of a single-center, prospective phase II study evaluating ibrutinib 420 mg once daily in 30 treatment-naive patients with Waldenstrom macroglobulinemia (WM). The present study is registered with ClinicalTrials.Gov (NCT02604511). With a median follow-up...

Cite
Castillo JJ, Meid K, Gustine JN, et al. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia. 2021;doi: 10.1038/s41375-021-01417-9.
Castillo, J. J., Meid, K., Gustine, J. N., Leventoff, C., White, T., Flynn, C. A., Sarosiek, S., Demos, M. G., Guerrera, M. L., Kofides, A., Liu, X., Munshi, M., Tsakmaklis, N., Xu, L., Yang, G., Branagan, A. R., O'Donnell, E., Raje, N., Yee, A. J., Patterson, C. J., Hunter, Z. R., & Treon, S. P. (2021). Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia, . https://doi.org/10.1038/s41375-021-01417-9
Castillo, Jorge J, et al. "Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia." Leukemia vol. (2021). doi: https://doi.org/10.1038/s41375-021-01417-9
Castillo JJ, Meid K, Gustine JN, Leventoff C, White T, Flynn CA, Sarosiek S, Demos MG, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, Xu L, Yang G, Branagan AR, O'Donnell E, Raje N, Yee AJ, Patterson CJ, Hunter ZR, Treon SP. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia. 2021 Sep 16; doi: 10.1038/s41375-021-01417-9. Epub 2021 Sep 16. PMID: 34531537.
Copy Download .nbib Format: NLM
Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome.

Blood

Jalink M, Berentsen S, Castillo JJ, Treon SP, Cruijsen M, Fattizzo B, Cassin R, Fotiou D, Kastritis E, De Haas M, Oosten LEM, Frederiksen H, Patriarca A, D'Sa S, Vos JMI.
PMID: 34293088
Blood. 2021 Nov 18;138(20):2002-2005. doi: 10.1182/blood.2021012039.

No abstract available.

Cite
Jalink M, Berentsen S, Castillo JJ, et al. Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. Blood. 2021;138(20):2002-2005doi: 10.1182/blood.2021012039.
Jalink, M., Berentsen, S., Castillo, J. J., Treon, S. P., Cruijsen, M., Fattizzo, B., Cassin, R., Fotiou, D., Kastritis, E., De Haas, M., Oosten, L. E. M., Frederiksen, H., Patriarca, A., D'Sa, S., & Vos, J. M. I. (2021). Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. Blood, 138(20), 2002-2005. https://doi.org/10.1182/blood.2021012039
Jalink, Marit, et al. "Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome." Blood vol. 138,20 (2021): 2002-2005. doi: https://doi.org/10.1182/blood.2021012039
Jalink M, Berentsen S, Castillo JJ, Treon SP, Cruijsen M, Fattizzo B, Cassin R, Fotiou D, Kastritis E, De Haas M, Oosten LEM, Frederiksen H, Patriarca A, D'Sa S, Vos JMI. Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. Blood. 2021 Nov 18;138(20):2002-2005. doi: 10.1182/blood.2021012039. PMID: 34293088.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 41 entries